CytRx Reports Positive Results from Global Phase 2b Clinical Trial with Aldoxorubicin in Advanced Soft Tissue Sarcomas
(NASDAQ: CYTR) today reported positive
results from additional statistical analyses that further support the
previously announced highly positive top-line efficacy results from a
multicenter, randomized, open-label global Phase 2b clinical trial
investigating the efficacy and safety of aldoxorubicin compared with
doxorubicin as first-line therapy in subjects with metastatic, locally
advanced or unresectable soft tissue sarcomas (STS).